This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bartholomeusz, B. Articles by Phillips, P. A. Search for Related Content PubMed PubMed Citation Articles by Bartholomeusz, B. Articles by Phillips, P. A.

(Hypertension. 1996;27:1341-1345.)
© 1996 American Heart Association, Inc.

Articles

Bosentan Ameliorates Cyclosporin A–Induced Hypertension in Rats and Primates

Briony Bartholomeusz; Kenneth J. Hardy; Angela S. Nelson; Paddy A. Phillips

From the Departments of Surgery (B.B., K.J.H.) and Medicine (P.A.P.), University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg, and Department of Obstetrics and Gynaecology (A.S.N.), University of Melbourne, Royal Women's Hospital, Carlton, Victoria, Australia.

Abstract Cyclosporine-induced hypertension is a major problem in transplant therapy. The pathophysiology of this disease is unclear. Cyclosporine increases endothelin synthesis and release, which may contribute to this hypertension. We examined the effects of chronic endothelin receptor blockade with the novel nonpeptide endothelin receptor antagonist bosentan in two animal models of cyclosporine-induced hypertension. Cyclosporine was administered daily to female Wistar rats (10 mg/kg per day SC for 30 days) and marmosets (30 mg/kg per day PO for 20 days). Control rats received vehicle. Tail-cuff systolic pressure was significantly elevated in the cyclosporine-treated animals before the last week of treatment. Bosentan (100 mg/kg) in arabic gum or arabic gum alone was given daily to the rats by gavage during the last 5 days of cyclosporine treatment and to the marmosets for the last 7 days of cyclosporine treatment. Tail-cuff systolic pressure was measured daily during bosentan treatment. Bosentan but not gum alone significantly lowered blood pressure in the cyclosporine-hypertensive rats from 134±1 to 122±3 mm Hg (P<.01) and in the cyclosporine-hypertensive marmosets from 156±2 to 139±4 mm Hg (P<.01). There were no differential effects on plasma creatinine concentration, endothelin concentration, or end-organ weights. Bosentan had no effect in the vehicle-treated rats. These data provide further evidence to support a role for endothelin in cyclosporine-induced hypertension and demonstrate the effectiveness of endothelin receptor antagonism as a novel treatment in cyclosporine-induced hypertension.

Key Words: cyclosporine • bosentan • endothelin • rats • primates

This article has been cited by other articles:

				A. Nishiyama, H. Kobori, T. Fukui, G.-X. Zhang, L. Yao, M. Rahman, H. Hitomi, H. Kiyomoto, T. Shokoji, S. Kimura, et al. Role of Angiotensin II and Reactive Oxygen Species in Cyclosporine A-Dependent Hypertension Hypertension, October 1, 2003; 42(4): 754 - 760. [Abstract] [Full Text] [PDF]

				J. Navarro-Antolin, J. Rey-Campos, and S. Lamas Transcriptional Induction of Endothelial Nitric Oxide Gene by Cyclosporine A. A ROLE FOR ACTIVATOR PROTEIN-1 J. Biol. Chem., February 4, 2000; 275(5): 3075 - 3080. [Abstract] [Full Text] [PDF]

				E. L. Schiffrin Role of Endothelin-1 in Hypertension Hypertension, October 1, 1999; 34(4): 876 - 881. [Abstract] [Full Text] [PDF]

				M. Hausberg, M. Barenbrock, H. Hohage, S. Muller, S. Heidenreich, and K.-H. Rahn ACE Inhibitor Versus ß-Blocker for the Treatment of Hypertension in Renal Allograft Recipients Hypertension, March 1, 1999; 33(3): 862 - 868. [Abstract] [Full Text] [PDF]

				S.-H. PARK, D. SALEH, A. GIAID, and R. P. MICHEL Increased Endothelin-1 in Bleomycin-induced Pulmonary Fibrosis and the Effect of an Endothelin Receptor Antagonist Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 600 - 608. [Abstract] [Full Text]